US Federal 2025-2026 Regular Session

US Federal Senate Bill SB1096

Introduced
3/24/25  
Refer
3/24/25  

Caption

Preserve Access to Affordable Generics and Biosimilars Act

Companion Bills

No companion bills found.

Previously Filed As

US A1510

Improves access to lower-cost generic and biosimilar drugs.

US A11256

Requires health plan coverage to include generic drugs and biosimilars where the wholesale acquisition cost of such generic drugs or biosimilars is lower than the brand drug's wholesale acquisition cost.

US SB393

Health Insurance - Prescription Drug Formularies and Coverage for Generic Drugs and Biosimilars

US HB529

Health Insurance - Prescription Drug Formularies and Coverage for Generic Drugs and Biosimilars

US HB870

Provides relative to formulary placement and cost-sharing requirements for certain generic drugs and biosimilars (RE1 NO IMPACT See Note)

US SB1414

Expedited Access to Biosimilars Act

US SB140

To Mandate The Use Of Biosimilar Medicines Under Health Benefit Plans; To Require A Healthcare Provider To Prescribe Biosimilar Medicines; And To Improve Access To Biosimilar Medicines.

US S03485

Relates to prescription drug formulary coverage for interchangeable biologics and biosimilars.

US A03973

Relates to prescription drug formulary coverage for interchangeable biologics and biosimilars.

US A08576

Relates to preserving access to affordable drugs; provides that an agreement resolving or settling, on a final or interim basis, a patent infringement claim, in connection with the sale of a pharmaceutical product, shall be presumed to have anticompetitive effects if a nonreference drug filer receives anything of value from another company asserting patent infringement and if the nonreference drug filer agrees to limit or forego research, development, manufacturing, marketing, or sales of the nonreference drug filer's product for any period of time.

Similar Bills

No similar bills found.